勤浩医药（苏州）股份有限公司获“D轮”融资，金额超3亿人民币

Group 1 - The core point of the article is that Qinhao Pharmaceutical (Suzhou) Co., Ltd. has recently completed a D-round financing of over 300 million RMB, indicating a significant step in its innovation and growth strategy [1] - Qinhao Pharmaceutical was established in 2014 and is primarily engaged in research and experimental development, with a registered capital of 15.732035 million RMB [1] - The company has made investments in three other enterprises and holds 29 patents and 7 trademarks, showcasing its commitment to intellectual property [1] Group 2 - The shareholders of Qinhao Pharmaceutical include Wang Kuifeng and several limited partnership firms, indicating a diverse ownership structure [1] - The financing round is part of the company's strategy to accelerate innovation and development in the pharmaceutical sector [1] - The D-round financing was completed in 2026, highlighting the company's forward-looking approach and planning [1]